Key Highlights
- 21% is the decline per published market data (October 16, 2026 premarket) for Curis (NASDAQ:CRIS), which traded at USD 0.4022 on relative volume of 1.49 and 368,350 shares. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026.
- USD 1.50 was the price of the August 13, 2026 offering of 3,733,334 shares by Curis (NASDAQ:CRIS), with matching five-year warrants at USD 1.75. The latest quote is 73% below the offering price, own arithmetic on two published numbers.
- USD 5.1 million of cash at June 30, 2026 compares with a six-month net loss of USD 32.8 million, per the 10-Q for the quarter ended June 30, 2026. Management states substantial doubt regarding going concern, and the offering added USD 4.8 million net.
- USD 840,630 is the market capitalization in published market data for Curis (NASDAQ:CRIS), which equals only 2.09 million shares and so omits the August offering. A 1-for-20 reverse split took effect on July 6, 2026, and royalty revenue ended with the November 2025 Erivedge sale.
Price Action and Catalyst Review
The decline was 20.83% to USD 0.4022 per published market data, implying a prior close of USD 0.508 (own arithmetic). Volume of 368,350 shares compares with an implied average of 247,000, so participation was modest. Turnover was USD 148,000 (price times volume, own arithmetic). No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. The latest capital event was the August 13, 2026 offering, gross proceeds USD 5.6 million (own arithmetic).
Capital Structure, Runway and Dilution
Curis reported USD 5.1 million of cash at June 30, 2026, plus USD 0.5 million restricted, against USD 18.6 million used in operations over six months. That is USD 3.1 million per month. Adding USD 4.8 million of net offering proceeds gives USD 9.9 million, a runway of 3.2 months from June 30, or the first week of October 2026 (own arithmetic, excluding any at-the-market sales not disclosed in the filings reviewed). An at-the-market program allows up to USD 100 million, capped at one-third of public float. Each share sold dilutes holders, and warrants add supply above the exercise price.
Pipeline, Share Count and Listing Risk
The lead drug emavusertib, an IRAK4 and FLT3 inhibitor, is in early clinical development, with the fifth patient dosed in a Phase 2 CLL combination trial on July 30, 2026. The 10-Q cover showed 2.09 million shares on August 11; adding the offering gives 5.82 million (own arithmetic), a market value of USD 2.34 million at USD 0.4022. A Nasdaq panel monitor through July 2027 is not independently confirmed in the filings reviewed; a further bid price shortfall would expose the shares to delisting.
Where Things Stand
Curis (NASDAQ:CRIS) fell 21% without an identified cause, so the move reflects microcap supply pressure more than a verdict on emavusertib. The balance of evidence is risk-led: going concern language, no royalty revenue after the Erivedge sale, a USD 0.4022 quote 73% below the August offering and a computed runway that ends in early October 2026 without further financing. Published market data show a Strong buy analyst consensus. Next dated events: third quarter results, expected in November 2026 without a confirmed date, trial updates and any new capital raise.






Please wait processing your request...